A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy.
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2016
At a glance
- Drugs CCX 140 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Therapeutic Use
- Sponsors ChemoCentryx
- 29 May 2015 According to a ChemoCentryx media release, phase II data, including important pre-specified subgroup analyses at future medical meetings will be presented.
- 29 May 2015 According to a ChemoCentryx media release, data from this trial was presented in the Late Breaking Clinical Trial session at the 52nd Annual European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress.
- 29 May 2015 Results published in the ChemoCentryx Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History